C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS) Tucson, AZ – December 18, 2017 Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium annou
C-Path and FARA announce collaborative data aggregation project for Friedreich’s ataxia Tucson, AZ, and Downingtown, PA — December 4, 2017 — Critical Path Institute‘s (C-Path) Data Colla
C-Path and CDISC Announce Therapeutic Area User Guide for Duchenne Muscular Dystrophy October 18, 2017 TUCSON, Ariz., and AUSTIN, Texas – October 18, 2017 –Critical Path Institute (C-Path) and The
C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntington’s Disease Therapeutic Area User Guide September 11, 2017 TUCSON, AZ, NEW YORK, NY, and AUSTIN, TX – September 11, 2017 – Critical Path Institute (C-Pa
C-Path and CDISC Announce Public Review Period for Duchenne Therapeutic Area Standard June 13, 2017 TUCSON, Ariz., and AUSTIN, Texas – June 13, 2017 – The Clinical Data Interchange Standards Consort
Critical Path Institute and TGen Forge Partnership to Advance TB Research May 1, 2017 Critical Path Institute and TGen Forge Partnership to Advance TB Research TUCSON and FLAGSTAFF, May 1,
Critical Path Institute Launches Transplant Therapeutics Consortium April 26, 2017 Critical Path Institute Launches Transplant Therapeutics Consortium Tucson, Ariz., April 26, 2017 –Critical Path
CDISC Announces New Standard for Major Depressive Disorder to Foster Development of New Treatments April 18, 2017 CDISC Announces New Standard for Major Depressive Disorder to Foster Development of New Treatments Austin, T
Critical Path Institute Launches Type 1 Diabetes Consortium March 20, 2017 Critical Path Institute Launches Type 1 Diabetes Consortium Tucson, Ariz., March 20, 2017 –Critical Path Institut
